Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab

Exclusion Criteria

• •Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
• •Participation in another ocular investigation or trial simultaneously
• •Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110)
• •Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
• •Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be contributing to the macular edema
• •An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy)
• •Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
• •Evidence of active neovascularization of the iris or retina
• •Evidence of central atrophy or fibrosis in the study eye
• •Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
• •Previous use of intraocular or periocular corticosteroids in the study eye in the previous 120 days
• •Previous treatment with anti-angiogenic drugs in the study eye i.e. pegaptanib sodium, bevacizumab, ranibizumab, aflibercept within 120 days prior to baseline
• •History of vitreous surgery in the study eye
• •History of cataract surgery within 3 months of enrollment.
• •History of YAG capsulotomy within 2 months of enrollment.
• •Visual acuity \<20/400 in the fellow eye
• •Uncontrolled glaucoma (pressure \>30) despite treatment with glaucoma medications.
• •History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.